Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) posted its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07, MarketWatch Earnings reports.
ACXP stock traded down $0.69 during mid-day trading on Friday, reaching $2.61. The company had a trading volume of 75,330 shares, compared to its average volume of 10,934. Acurx Pharmaceuticals has a one year low of $2.61 and a one year high of $8.74. The stock’s 50-day simple moving average is $3.69 and its two-hundred day simple moving average is $4.18.
A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. BlackRock Inc. increased its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) by 149.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,699 shares of the company’s stock after purchasing an additional 10,014 shares during the quarter. BlackRock Inc. owned approximately 0.16% of Acurx Pharmaceuticals worth $55,000 as of its most recent filing with the Securities and Exchange Commission. 0.72% of the stock is currently owned by hedge funds and other institutional investors.
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.